This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2006 by University of Oxford.
Recruitment status was:  Active, not recruiting
Merck KGaA
Information provided by:
University of Oxford Identifier:
First received: October 3, 2005
Last updated: January 26, 2007
Last verified: September 2006

AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients with established atherosclerosis. The investigators will therefore study patients with atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic resonance imaging (MRI).

AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with coronary artery disease and type II diabetes mellitus, who typically have low high-density lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.

Condition Intervention
Atherosclerosis Drug: Niaspan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function

Resource links provided by NLM:

Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Regression of artheriosclerotic plaque measured using functional magnetic resonance imaging.

Estimated Enrollment: 70
Study Start Date: September 2004
Estimated Study Completion Date: February 2009
Detailed Description:
Patients will be randomised to receive either Niaspan 2000mg each night or placebo. Niaspan will be commenced at 375mg daily and increased to 500mg then to 750, and 1000mg daily at weekly intervals. After 4 weeks the dose will be increased to 1500mg daily and, after a further one month, the study dose of 2000mg daily2 will be instigated. Immediately before randomization (to exclude patients unable to tolerate MRI because of claustrophobia), and 6 and 12 months after commencing treatment participants will undergo MR examination.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aim 1: Carotid or peripheral arterial disease and HDL <1mmol/L
  • Aim 2: Coronary artery disease, type II diabetes and HDL <1mmol/L

Exclusion Criteria:

The following will constitute exclusion criteria:

  • Inability to provide informed consent,
  • Known intolerance of a study drug,
  • Use of niacin or a fibrate at time of screening,
  • AST or ALT elevated above normal range at time of screening
  • Use of oral nitrates or nicorandil
  • Uncontrolled or newly diagnosed diabetes mellitus
  • Symptomatic heart failure or heart failure requiring treatment with diuretics
  • Fasting triglycerides > 500mg/dL [5.65mmol/L]
  • Patients with acute coronary syndromes, active peptic ulcer disease,
  • Active gout,
  • Standard exclusions for MRI will apply, i.e. pacemakers, implantable defibrillators, metal implants or embedded metallic fragments of any kind.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00232531

United Kingdom
Oxford University
Oxford, United Kingdom
Sponsors and Collaborators
University of Oxford
Merck KGaA
Principal Investigator: Robin P Choudhury, DM, MRCP University of Oxford
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00232531     History of Changes
Other Study ID Numbers: 04.OXA.020
Study First Received: October 3, 2005
Last Updated: January 26, 2007

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Nicotinic Acids
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on September 21, 2017